Tenured Professor, University of British Columbia, Canada
Heart Stroke Foundation of BC and Yukon
Fellow, The Royal Society of Canada, 2006.
International Researcher, Howard Hughes Medical Institute (HHMI), from 2001 to 2011
Won the Canadian Innovation Award for Neurological and Psychopharmacological Research in 2017
Overseas Review Expert of the Chinese Academy of Sciences
Overseas Review Expert of the Natural Science Foundation of China
Overseas Review Expert of the Changjiang Scholar Program of the Ministry of Education
Overseas Expert & Advisory Committee Member of the Overseas Chinese Affairs Office of the State Council of the People's Republic of China
Honorary Dean, Institute of Nerve Regeneration and Rehabilitation, Qingdao University
Academician Wang Yutian is deeply involved in researching the mechanism behind major neurological diseases and the development of innovative drugs. In particular, he has achieved internationally leading results in the development of specific drugs for learning and memory disorders, cerebral stroke, drug addiction, Alzheimer's disease, depression, and other central nervous system diseases, and has acquired numerous internationally protected drug patents.
Academician Wang Yutian has over a decade of experience in successfully managing and operating pharmaceutical enterprises. As one of the founders of Canada's NoNO Inc. Pharmaceutical Company, he shared data at the World Cerebral Stroke Conference in February 2020 on NA-1, a neuroprotective agent whose development he was involved in, which has completed an international multi-center Phase III clinical trial. NA-1 is the first neuroprotective agent to display protective functions for the brain in the past 50 years of global research. Moreover, he is also one of the founders of Canada's Primary Peptides Pharmaceutical Company, which authorized Suzhou Yabao Pharmaceutical Research and Development Co., Ltd. to conduct research on its SY-007 polypeptide project. The project has currently entered phase I clinical trial in China.
Bachelor of Science, Department of Biotechnology, School of Life Sciences, Peking University
Master of Neuroscience, University of British Columbia, Faculty of Medicine, Canada
Yan Yi’s is primarily involved in researching the mechanism of synaptic plasticity in the nervous system and the pathogenesis of related nervous system diseases. He is also deeply involved in researching the function of Akt in AMPA receptor trafficking and the resulting long-term potentiation (LTP), which can reveal the possible mechanism of Akt action and provide new targets and directions for treating related diseases and drug development. Furthermore, he has studied the mechanism of neuropeptides and their receptors in mediating synaptic plasticity and pain sensitivity in the central nervous system. His research results have brought light on the possible direction to further clarify the pain mechanism. Apart from years of scientific research experience, he has successful experience in running and managing companies, and in building teams and developing corporate culture. He has a strict and disciplined work style, and is highly capable and has excellent communication skills.
Professor of Qingdao University, National Outstanding Youth, Vice Minister of Medical Center, Dean of the Institute of Nerve Regeneration and Rehabilitation
Vice Minister of Medical Center, Vice Dean of Medical Research Institute, Vice Minister of Postgraduate Education and International Exchange of Wuhan University
Tenured Professor, University of Nevada, USA
Senior Scientist, University of Toronto, Canada
Wan Qi is the winner of the Canadian HSF and MRC Fellowship Awards and Canadian Research Foundation Awards. He has also published his works in Nature, Nature Neuroscience, Nature Medicine and other renowned publications, and has been invited to publish review articles in Trends in Neuroscience.
Copyright © 2020 Qingdao Primedicine Pharmaceutical Technology Co., Ltd. All right reserved
